While last year's positive readout from the first part of Array Biopharma Inc.'s phase III COLUMBUS trial testing binimetinib and encorafenib in BRAF-mutant advanced, unresectable or metastatic melanoma cleared the way for regulatory filings, supplementary results from the study's second part, released late Tuesday, could bolster the combination's prospects for approval and market penetration.